CN113975289A - Application of sulfated fucogalactomannoglucuronan polysaccharide from brown algae in anti-aging - Google Patents
Application of sulfated fucogalactomannoglucuronan polysaccharide from brown algae in anti-aging Download PDFInfo
- Publication number
- CN113975289A CN113975289A CN202111382619.XA CN202111382619A CN113975289A CN 113975289 A CN113975289 A CN 113975289A CN 202111382619 A CN202111382619 A CN 202111382619A CN 113975289 A CN113975289 A CN 113975289A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- sulfated
- aging
- sargassum
- brown algae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 94
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 94
- 150000004676 glycans Chemical class 0.000 title claims abstract description 92
- 241000199919 Phaeophyceae Species 0.000 title claims abstract description 24
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 27
- 239000002253 acid Substances 0.000 claims abstract description 23
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims abstract description 22
- 230000032683 aging Effects 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000014509 gene expression Effects 0.000 claims abstract description 12
- 230000006870 function Effects 0.000 claims abstract description 10
- 230000002708 enhancing effect Effects 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 230000032677 cell aging Effects 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 241000195474 Sargassum Species 0.000 claims description 25
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 150000002772 monosaccharides Chemical class 0.000 claims description 15
- 230000009758 senescence Effects 0.000 claims description 15
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 15
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 14
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 14
- 229940097043 glucuronic acid Drugs 0.000 claims description 14
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 11
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 11
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 11
- 230000000593 degrading effect Effects 0.000 claims description 11
- 101000697844 Arabidopsis thaliana Thiosulfate sulfurtransferase 16, chloroplastic Proteins 0.000 claims description 9
- 241001262105 Sargassum muticum Species 0.000 claims description 9
- 241000593522 Sargassum thunbergii Species 0.000 claims description 9
- 241001261506 Undaria pinnatifida Species 0.000 claims description 9
- 230000003833 cell viability Effects 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000022131 cell cycle Effects 0.000 claims description 8
- 229930182830 galactose Natural products 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 210000004153 islets of langerhan Anatomy 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 6
- 230000010094 cellular senescence Effects 0.000 claims description 6
- 241000264279 Sargassum fusiforme Species 0.000 claims description 5
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 claims description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 3
- 102100030304 Platelet factor 4 Human genes 0.000 claims description 3
- 108700012920 TNF Proteins 0.000 claims description 3
- 230000008439 repair process Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000000979 retarding effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 238000003756 stirring Methods 0.000 description 28
- 230000003472 neutralizing effect Effects 0.000 description 20
- 238000000643 oven drying Methods 0.000 description 19
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 18
- 229910001629 magnesium chloride Inorganic materials 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- 238000000502 dialysis Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 14
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 13
- 229920001543 Laminarin Polymers 0.000 description 13
- 239000005717 Laminarin Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000006820 DNA synthesis Effects 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 241000195493 Cryptophyta Species 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 229920000855 Fucoidan Polymers 0.000 description 6
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 5
- 241000593520 Sargassum hemiphyllum Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 4
- 241000015177 Saccharina japonica Species 0.000 description 4
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 3
- 241001466453 Laminaria Species 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 241001475537 Sargassum integerrimum Species 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 241000195480 Fucus Species 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- -1 sal ammoniac polysaccharide Chemical class 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 230000037060 G2 phase arrest Effects 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010070626 acid beta-galactosidase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The invention discloses an application of sulfated fucogalactomannosyluronic acid polysaccharide from brown algae in anti-aging, which is used for solving the problems of large side effect and common effect of the existing anti-aging drugs, wherein the application of the sulfated fucogalactomannosyluronic acid polysaccharide from brown algae in anti-aging achieves the aim of anti-aging by enhancing cell activity, delaying cell aging, improving the expression of aging-related proteins of islet beta cells and improving the functions of the islet beta cells.
Description
Technical Field
The invention relates to the field of pharmacy, in particular to application of sulfated fucalactoglucuronan polysaccharide from brown algae in anti-aging.
Background
After the 21 st century, people have been confronted with a serious challenge of population aging, and many countries (including China) have entered the population aging society, and the elderly people aged at 60 or more account for more than 10% of the total population. At present, the elderly (including a part of middle-aged people) in China are seriously troubled by aging, and the health condition and the life quality of the elderly are directly influenced. How to completely explain the pathogenesis of aging and how to improve the health condition and the life quality of the old people is a problem which needs to be solved by researchers at present. In recent years, with the development of science and technology and the continuous improvement of research means, the focus of modern people is the western anti-aging mechanism and the medicinal potential of the Chinese herbal medicines, and the Chinese herbal medicines show great attractive prospects.
Cellular senescence refers to the irreversible, permanent state of cell cycle arrest that cells cause after stress. Cell damage itself does not directly lead to obvious signs of aging, but when the damage accumulates and reaches a certain limit, the cells stop proliferating, resulting in a macroscopically weak tissue and a physiological aging phenotype. Several senescence-inducing factors (including DNA damage, oncogenic mutations, active metabolites, high mitogen and trophic signals increase mTOR activity, protein toxicity stress) may act alone or in concert on cells, causing cellular senescence through the p16INK4a/Rb, p53/p21 pathway, or other pathways. These may lead to widespread gene expression changes and chromatin remodeling (formation of heterochromatin), which underlie SASP, senescence-associated growth arrest, and morphological changes.
Studies have shown that aging and diabetes are related. The prevalence rate of diabetes and pre-diabetes remarkably increases with age, and the proliferation potential of islet beta cells remarkably decreases with age, so that the prevalence rate of diabetes in the elderly is increased, and the diabetes is an age-related disease. With the aging, the secretion function of islet beta cells is reduced, the regeneration capacity of the cells is reduced, and the islet beta cells are aged and accumulated, so that the glucose tolerance is reduced and the diabetes mellitus is caused. At the same time, the aging can also cause the apoptosis of the islet beta cells to increase, and further influence the function of the islet beta cells. Aging of islet beta cells is not only age-related, but is also affected by other factors, such as obesity and abnormal glycolipid metabolism, which increase the number of aging cells in the body and accelerate cellular aging. When cells undergo senescence, a universal marker with the senescence phenotype, senescence-associated acid beta-galactosidase activity, p21Cis1， p16Ink4aIncreased expression in the senescent cells and,meanwhile, the proportion of Ki67 positive cells is obviously reduced, the compensatory hyperplasia of the pancreatic island is inhibited, and the secretion factor of the secretion spectrum (SASP) related to aging is increased. Although the relationship between islet beta cell senescence and diabetes is very clear, the concerns of diabetes caused by senescent islet cells are relatively low, and the development process of the medicine is restricted.
Chinese medicine resources are rich in China, and at present, a lot of anti-aging medicines are available, wherein the Chinese medicine polysaccharide has good anti-aging activity. Compared with traditional medicines, polysaccharide medicines are not medicines, do not have any toxicity, but can bring about various pharmacological activities, and nowadays when people pay more attention to the toxicity of medicines, polysaccharide can effectively resist various chronic diseases of chemical medicines which treat symptoms but not root causes. The marine polysaccharide is derived from organisms in a unique marine ecological environment, the synthesized components have distinct marine characteristics and unique chemical characteristics, and present unique pharmacological activity, the safety is high, the toxic and side effects are small, and the like, so that the marine polysaccharide becomes a new trend of drug development.
The marine brown algae has various polysaccharides with complex structures, and only sulfated polysaccharides include three major groups, one is fucoidan sulfate (also called fucoidan sulfate), which is a sulfated polysaccharide component with fucose as a constituent monosaccharide, the other is sulfated polysaccharide with fucose and galactose, namely galactofucoidan sulfate, besides, brown algae also commonly has a low sulfated heteroglycan rich in uronic acid, which has complex monosaccharide composition and contains various monosaccharides such as mannose, glucuronic acid, fucose and galactose, and when the sulfated polysaccharide component in brown algae is subjected to fractional purification by anion gel chromatography, the low sulfated heteroglycan component containing glucuronic acid is generally eluted by low-concentration electrolyte firstly. Due to the large difference of chemical characteristics, the biological activities of the low sulfated heteroglycan and the fucoidan sulfate are greatly different. For example, Croci et al reported that two sulfated polysaccharides were isolated from brown algae Laminaria saccharophila, one belonging to the low sulfated heteroglycan species known as fucomannoglucuronan (fucoidan) and the other fucoidan, and their comparative studies on the activity of the two different polysaccharides concluded that fucoidan, but not fucomannoglucuronan, determined the biological activity of the sulfated polysaccharides in brown algae Laminaria saccharophila, including anticoagulant, antitumor, anti-inflammatory, etc. activities. (fungi, but not fungal polysaccharides, degraded polysaccharides from Laminaria saccharona brown seaweed, PLoS ONE2011,6(2): 1-10). We found that low sulfated heteroglycan had significant efficacy in treating parkinson's disease and also in treating and/or preventing type 2 diabetes in the early days, and further found that sulfated fucogalactomannoglucuronan polysaccharide (structurally similar to low sulfated heteroglycan) had significant effects in anti-aging.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, clarifies a new application and an action mechanism of sulfated fucalactoglucuronan polysaccharide from brown algae according to multiple cell experiments, and performs experimental verification.
The invention is realized by the following technical scheme:
in order to achieve the purpose, the invention provides an application of sulfated fucogalactomannoglucuronate polysaccharide derived from brown algae in anti-aging, which is characterized in that the sulfated fucogalactomannoglucuronate polysaccharide derived from brown algae achieves the aim of anti-aging by enhancing cell activity, delaying cell aging, improving the expression of aging-related protein of islet beta cells and improving the function of the islet beta cells.
Preferably, the enhancing cell viability is enhancing the viability of the beta cell line.
Preferably, the delaying of cellular senescence is repairing cell cycle changes.
Preferably, the above-mentioned improvement of the expression of senescence-associated proteins of islet beta cells is to reduce the expression of senescence-associated proteins p53, p21 and p16, while alleviating senescence-associated secretory phenotypes IL-1 beta, TNFa, CXCL4 and CXCL 10.
Preferably, the function of the islet beta cells is to repair insulin synthesis damage of the islet cells.
Preferably, the sulfated fucogalactomannoglucuronate polysaccharide mainly comprises monosaccharides including glucuronic acid, mannose, galactose and fucose; the content of hydrolyzed sulfate group is 2-12%, the content of fucose is 3-10%, and the content of uronic acid is 20-40%.
The sulfated fucalactoglucuronan polysaccharide has the following structural characteristics:
(1) the component sugar comprises: mannose, glucuronic acid, galactose, fucose;
(2) mannose and glucuronic acid are linked by an alpha (1 → 4) glycosidic bond; glucuronic acid and mannose are linked by a β (1 → 2) glycosidic bond;
(3) the glucuronic acid and the glucuronic acid are connected by a beta (1 → 3) glycosidic bond;
(4) galactose is mainly connected by beta (1 → 6) glycosidic bond;
(5) fucose is connected with alpha (1 → 3) glycosidic bond, C2 or C4 site is sulfated; or mannose linked in a branched form by an alpha (1 → 3) glycosidic linkage;
(6) comprises the following structural units (I), (II), (III) and (IV) which are alternately connected with each other;
wherein R is1Is H or a sulfate radical, R2Is a sulfated fucose residue.
Preferably, the sulfated fucus galactomannosyluronic acid polysaccharide is derived from marine brown algae, wherein the marine brown algae comprises one or more of sea tangle, Undaria pinnatifida, Sargassum hemiphyllum, Sargassum thunbergii, Sargassum integrifolia, Cyrtymenia Sparsa, Sargassum salmonicum, Sargassum muelleri, and Sargassum muticum.
Preferably, the molecular weight of the sulfated fucogalactomannoglucuronan polysaccharide is 1kD to 1000 kD.
Preferably, the above method of application is the administration of an effective amount of sulfated fucgalactomannoglucuronan polysaccharide as a medicament.
Preferably, the above-mentioned medicament is a pharmaceutically acceptable carrier or dosage form.
The invention also provides a preparation method of the brown algae-derived sulfated fucgalactomannosylglucuronic acid polysaccharide, which comprises the following steps: extracting water-soluble polysaccharide from marine brown algae by water extraction; and finally, degrading by using high-concentration acid and precipitating by using alcohol to obtain the water-soluble polysaccharide with stable strong acid.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention has obvious anti-aging effect, small toxic and side effect, safety and effectiveness, and can be used for preparing anti-aging medicaments.
(2) According to the invention, after research, the sulfated fucus galactomannogalacturonic acid polysaccharide from brown algae has a very good treatment effect on anti-aging, no other colleges or institutions have researched in the direction at present, and the technical progress of the scheme of the invention is relatively great, thereby being beneficial to market popularization.
Drawings
FIG. 1 is SA-beta-gal staining of different SFGGs
FIG. 2 is a diagram of cell motility; wherein A is the influence of SFGG-SJ addition on the vitality of MIN6 cells; b is H2O2Effect of addition of SFGG-SJ on cell viability after treatment.
FIG. 3 is a graph of the cell cycle changes caused by SFGG-SJ versus H2O 2; wherein S is: a DNA synthesis period; g1 is: DNA synthesis earlier stage; g2 is: late stage of DNA synthesis;
FIG. 4 is the expression of cellular senescence-associated proteins after SFGG-SJ treatment;
FIG. 5 is a graph of the change in senescence-associated secretory phenotype after SFGG-SJ treatment;
FIG. 6 is a model of aging after SFGG-SJ treatment.
Detailed Description
The present invention will be described in more detail with reference to examples. It is to be understood that the practice of the invention is not limited to the following examples, and that various changes or modifications may be made therein without departing from the scope of the invention; and the methods in the following examples are conventional in the art unless otherwise specified.
Example 1: preparation of Laminaria japonica-derived fucogalactomannoglucuronan (SFGG-SJ)
(1) Extracting 1kg of kelp by 15 times of water in a pressure cooker for 3 hours, and controlling the temperature to be 100-; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to final mass concentration of 0.05mol/L to obtain ethanol with final weight concentration of 20%, stirring to obtain precipitate, centrifuging to remove precipitate, dialyzing with 3500Da molecular weight cutoff dialysis bag for 2 days, concentrating the solution in dialysis bag, and lyophilizing to obtain laminarin A with yield of 1.5%.
(2) Dissolving laminarin A in water to prepare a solution with the concentration of 1 percent (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.1mol/L, stirring for 2 hours in a water bath with the temperature of 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into absolute ethyl alcohol with the same volume. Centrifuging, and oven-drying with infrared to obtain laminarin B with yield of 53.5%.
(3) Dissolving laminarin B in water to prepare a solution with the concentration of 1 percent (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.5mol/L, stirring and degrading for 2 hours in a water bath with the temperature of 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into absolute ethyl alcohol with the same volume. Centrifuging, and oven-drying with infrared to obtain laminarin C with yield of 40.4%.
(4) Dissolving laminarin C (0.5G) in 4 ml of 0.2M ammonium bicarbonate, loading to column chromatography with Bio-Gel P-10 as a carrier, taking 0.2M ammonium bicarbonate as a mobile phase, collecting an elution component, concentrating the elution component, loading to column chromatography desalting with Sephadex G10 as a carrier, concentrating an eluent, and freeze-drying to obtain the fucogalactomannan uronic acid polysaccharide (SFGG-SJ) from the kelp, wherein the yield is 80.5%. The SFGG-SJ components were analyzed for chemical components, monosaccharide ratios, sulfate content and molecular weight, and the results are shown in table 1 below.
Example 2: preparation of sea-tangle-derived low-molecular-weight fucogalactomannoglucuronan polysaccharide (DSFGG-SJ)
(1) Dissolving laminarin A in water to prepare a solution with the concentration of 1 percent (mass concentration), adding 30mM ascorbic acid and 30mM hydrogen peroxide, and reacting for 2 hours at normal temperature. The reaction solution was dialyzed with a dialysis bag having a molecular weight cutoff of 3500Da in tap water and distilled water, respectively, and then concentrated and lyophilized. Obtaining the low molecular weight laminarin D.
(2) Dissolving low molecular weight laminarin D in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.1mol/L, stirring for 2 hours in a water bath of 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into absolute ethyl alcohol with the same volume. Centrifuging, and oven-drying with infrared to obtain laminarin E with yield of 55.7%.
(3) Dissolving laminarin E in water to prepare a solution with the concentration of 1 percent (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.5mol/L, stirring and degrading for 2 hours in a water bath with the temperature of 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into absolute ethyl alcohol with the same volume. Centrifuging, and oven-drying with infrared to obtain laminarin F with yield of 48.5%.
(4) Dissolving laminarin F (0.5G) in 4 ml of 0.2M ammonium bicarbonate, loading to column chromatography with Bio-Gel P-10 as a carrier, taking 0.2M ammonium bicarbonate as a mobile phase, collecting an elution component, concentrating the elution component, loading to column chromatography with Sephadex G10 as a carrier for desalting, concentrating an eluent, and freeze-drying to obtain the fucogalactomannan uronic acid polysaccharide (DSFGG-SJ) from the kelp, wherein the yield is 85.3%. The DSFGG-SJ component was analyzed for chemical components, monosaccharide ratio, sulfate content and molecular weight, and the results are shown in Table 1 below.
Example 3: preparation of fucogalactomannoglucuronan (SFGG-SH) derived from Sargassum hemiphyllum
(1) Extracting 1kg of half-leaf gulfweed with 15 times of water in a pressure cooker for 3 hours, and controlling the temperature to be 100-105 ℃; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to final weight concentration of 20% to obtain ethanol final weight concentration of 0.05mol/L, stirring to obtain precipitate, centrifuging to remove precipitate, dialyzing with 3500Da molecular weight cutoff dialysis bag for 2 days, concentrating, and dialyzingThe inner solution is freeze-dried to obtain the sargassum semilaevis polysaccharide A, and the yield is 4.6%.
(2) Dissolving sargassum semialatum polysaccharide A in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.1mol/L, stirring for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven drying with infrared to obtain Sargassum hemiphyllum polysaccharide B with yield of 60.5%.
(3) Dissolving sargassum semialatum polysaccharide B in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.5mol/L, stirring and degrading in a water bath at 80 ℃ for 2 hours, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven-drying with infrared to obtain Sargassum hemiphyllum polysaccharide SFGG-SH with yield of 43.3%. The SFGG-SJ components were analyzed for chemical components, monosaccharide ratios, sulfate content and molecular weight, and the results are shown in table 1 below.
Example 4: preparation of fucogalactomannosyluronic acid polysaccharide (SFGG-SF) derived from Cyrtymenia Sparsa
(1) Extracting 1kg of sargassum fusiforme in a pressure cooker for 3 hours by using water with the mass 15 times, and controlling the temperature to be 100-105 ℃; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to final mass concentration of 0.05mol/L to make ethanol final weight concentration 20%, stirring to generate precipitate, centrifuging to remove precipitate, dialyzing with 3500Da molecular weight cutoff dialysis bag for 2 days, concentrating the solution in dialysis bag, and lyophilizing to obtain Sargassum fusiforme polysaccharide A with yield of 3.5%.
(2) Dissolving sargassum fusiforme polysaccharide A in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.1mol/L, stirring for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven drying with infrared to obtain Sargassum fusiforme polysaccharide B with yield of 40.5%.
(3) Dissolving Cyrtymenia Sparsa polysaccharide B in water to obtain 1% (mass concentration) solution, adding 4mol/L hydrochloric acid to make final concentration 0.5mol/L, stirring in 80 deg.C water bath for degradation for 2 hr, neutralizing with sodium hydroxide, concentrating, and adding into equal volume of anhydrous ethanol. Centrifuging, and oven drying with infrared to obtain Sargassum hemiphyllum polysaccharide SFGG-SF with yield of 33.3%. The SFGG-SF components were analyzed for chemical components, monosaccharide ratios, sulfate content and molecular weight, and the results are shown in table 1 below.
Example 5: preparation of fucogalactomannosyluronic acid polysaccharide (SFGG-ST) derived from Sargassum thunbergii
(1) Extracting 1kg of sargassum thunbergii with 15 times of water in a pressure cooker for 3 hours, and controlling the temperature to be 100-105 ℃; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to final mass concentration of 0.05mol/L to make ethanol final weight concentration 20%, stirring to generate precipitate, centrifuging to remove precipitate, dialyzing with 3500Da molecular weight cutoff dialysis bag for 2 days, concentrating solution in dialysis bag, and lyophilizing to obtain Sargassum thunbergii polysaccharide A with yield of 5.8%.
(2) Dissolving sargassum thunbergii polysaccharide A in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.1mol/L, stirring for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven drying with infrared to obtain Sargassum thunbergii polysaccharide B with yield of 37.3%.
(3) Dissolving sargassum thunbergii polysaccharide B in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.5mol/L, stirring and degrading in a water bath at 80 ℃ for 2 hours, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven drying with infrared to obtain Sargassum thunbergii polysaccharide SFGG-ST with yield of 31.2%. The SFGG-ST fraction was analyzed for chemical composition, monosaccharide ratio, sulfate content and molecular weight, and the results are shown in table 1 below.
Example 6: preparation of fucogalactomannoglucuronan (SFGG-UP) derived from Undaria pinnatifida
(1) Extracting 1kg of undaria pinnatifida in a pressure cooker for 3 hours by using 15 times of water, and controlling the temperature to be 100-105 ℃; extracting for 1 time. Removing algae, mixing extractive solutions, and adding diatomiteFiltering, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to final mass concentration of 0.05mol/L to obtain ethanol with final weight concentration of 20%, stirring to obtain precipitate, centrifuging to remove precipitate, dialyzing with 3500Da dialysis bag for 2 days, concentrating the solution in the dialysis bag, and lyophilizing to obtain Undaria pinnatifida polysaccharide A with yield of 2.5%.
(2) Dissolving Undaria pinnatifida polysaccharide A in water to obtain a solution with a concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to make the final concentration of 0.1mol/L, stirring for 2 hours in 80-degree water bath, neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven drying with infrared to obtain Undaria pinnatifida polysaccharide B with yield of 38.2%.
(3) Dissolving Undaria pinnatifida polysaccharide B in water to obtain a solution with a concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to make the final concentration of 0.5mol/L, stirring and degrading in 80 ℃ water bath for 2 hours, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven drying with infrared to obtain Undaria pinnatifida polysaccharide SFGG-UP with yield of 30.8%. The SFGG-UP component was analyzed for chemical components, monosaccharide ratio, sulfate content and molecular weight, and the results are shown in Table 1 below.
Example 7: preparation of fucogalactomannoglucuronan (SFGG-SHO) derived from Sargassum muticum
(1) Extracting 1kg of sargassum muticum with 15 times of water in a pressure cooker for 3 hours, and controlling the temperature at 100 ℃ and 105 ℃; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to a final mass concentration of 0.05mol/L to make the final weight concentration of ethanol be 20%, stirring to generate precipitate, centrifuging to remove precipitate, dialyzing with a dialysis bag with molecular weight cutoff of 3500Da for 2 days, concentrating the solution in the dialysis bag, and lyophilizing to obtain Sargassum muticum polysaccharide A with yield of 1.8%.
(2) Dissolving sargassum muticum polysaccharide A in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.1mol/L, stirring for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven-drying with infrared to obtain Sargassum muticum polysaccharide B with yield of 43.2%.
(3) Dissolving sargassum muticum polysaccharide B in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.5mol/L, stirring and degrading in a water bath at 80 ℃ for 2 hours, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and baking by infrared to obtain sargassum muticum polysaccharide SFGG-SHO with the yield of 35.2%. The SFGG-SHO components were analyzed for chemical components, monosaccharide ratios, sulfate content and molecular weight, and the results are shown in table 1 below.
Example 8: preparation of fucogalactomannoglucuronan (SFGG-SN) derived from Sargassum Ammoniacus
(1) Extracting 1kg of sargassum sal ammoniac with 15 times of water in a pressure cooker for 3 hours, and controlling the temperature at 100-; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to final mass concentration of 0.05mol/L to obtain ethanol with final weight concentration of 20%, stirring to obtain precipitate, centrifuging to remove precipitate, dialyzing with 3500Da molecular weight cutoff dialysis bag for 2 days, concentrating the solution in the dialysis bag, and lyophilizing to obtain Sargassum Ammoniacus polysaccharide A with yield of 5.5%.
(2) Dissolving sargassum sal ammoniac polysaccharide A in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.1mol/L, stirring for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven-drying with infrared to obtain Sargassum salmianum polysaccharide B with yield of 50.2%.
(3) Dissolving sargassum sal ammoniac polysaccharide B in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to enable the final concentration to be 0.5mol/L, stirring and degrading for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven-drying with infrared to obtain Sargassum salmianum polysaccharide SFGG-SN with yield of 41.3%. The SFGG-SN components were analyzed for chemical components, monosaccharide ratios, sulfate content and molecular weight, and the results are shown in Table 1 below.
Example 9: preparation of fucogalactomannoglucuronan (SFGG-SI) derived from Sargassum integerrimum
(1) Extracting 1kg of sargassum integerrimum in 15 times of water in a pressure cooker for 3 hours, and controlling the temperature to be 100-105 ℃; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2The final mass concentration is 0.05mol/L, and simultaneously absolute ethyl alcohol is added to make the final weight concentration of the ethyl alcohol be 20%, the mixture is stirred to generate precipitate, the precipitate is removed by centrifugation, dialyzed for 2 days by a dialysis bag with the molecular weight cutoff of 3500Da, the solution in the dialysis bag is concentrated, and freeze-dried to obtain the sargassum integrifolium polysaccharide A, and the yield is 4.2%.
(2) Dissolving sargassum integrifolium polysaccharide A in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.1mol/L, stirring for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into absolute ethyl alcohol with the same volume. Centrifuging, and oven drying with infrared to obtain Sargassum integerrimum polysaccharide B with yield of 46.1%.
(3) Dissolving sargassum integrifolium polysaccharide B in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.5mol/L, stirring and degrading in a water bath at 80 ℃ for 2 hours, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven drying with infrared to obtain Sargassum integrifolia polysaccharide SFGG-SI with yield of 39.8%. The SFGG-SI components are analyzed for chemical components, monosaccharide ratio, sulfate radical content, molecular weight and the like, and the results are shown in the following table 1.
Example 10: preparation of fucogalactomannoglucuronan (SFGG-SM) derived from Sargassum muelleri
(1) Extracting 1kg of gulfweed with 15 times of water in a pressure cooker for 3 hours, and controlling the temperature at 100-105 ℃; extracting for 1 time. Removing algae, mixing extractive solutions, vacuum filtering with diatomite, concentrating the filtrate, adding 2mol/L MgCl2Making MgCl2Adding anhydrous ethanol to final weight concentration of 20% to obtain ethanol final weight concentration of 0.05mol/L, stirring to obtain precipitate, centrifuging to remove precipitate, dialyzing with 3500Da molecular weight cutoff dialysis bag for 2 days, concentrating, and dialyzingThe solution is freeze-dried to obtain the sargassum morganii polysaccharide A, and the yield is 5.2%.
(2) Dissolving sargassum morganii polysaccharide A in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.1mol/L, stirring for 2 hours in a water bath at 80 ℃, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven-drying with infrared to obtain Sargassum muelleri polysaccharide B with yield of 37.3%.
(3) Dissolving sargassum morganii polysaccharide B in water to prepare a solution with the concentration of 1% (mass concentration), adding 4mol/L hydrochloric acid to ensure that the final concentration is 0.5mol/L, stirring and degrading in a water bath at 80 ℃ for 2 hours, then neutralizing with sodium hydroxide, concentrating, and pouring into anhydrous ethanol with the same volume. Centrifuging, and oven-drying with infrared to obtain Sargassum muelleri polysaccharide SFGG-SM with yield of 35.2%. The SFGG-SM fraction was analyzed for chemical components, monosaccharide ratios, sulfate content and molecular weight, and the results are shown in table 1 below.
Example 11: effect of fucogalactomannosyluronic acid polysaccharide (SFGG) derived from brown algae on MIN6 cell viability
MIN6 is mouse islet beta cell line, has good insulin secretion function, and is a common cell line for researching islet function. After islet beta cells MIN6 were pretreated with hydrogen peroxide, 100. mu.g/ml SFGG from examples 1-10 was added for drug treatment for 24h, and CCK8 was used to test cell viability. Table 2 summarizes the effect of SFGG on improving the reduction in cell viability of MIN6 caused by hydrogen peroxide in examples 1-10.
TABLE 2 MIN6 cell viability following different SFGG treatments
Example 12: brown algae-derived fucogalactomannosyluronic acid polysaccharide (SFGG) for delaying MIN6 cell aging
After MIN6 cells were pretreated with hydrogen peroxide, SFGG was added at a concentration of 100. mu.g/ml in examples 1-10 for drug treatment for 24h, as shown in FIG. 1, staining with senescence-associated galactosidase SA-. beta. -gal clearly shows that SFGG can significantly reduce senescent cells.
Example 13: laminaria japonica-derived fucogalactomannosyluronic acid polysaccharide (SFGG-SJ) capable of enhancing cell viability of MIN6
After MIN6 cells were pretreated with hydrogen peroxide, different concentrations of the polysaccharides of example 1 were added for drug treatment for 24h, and the results in FIG. 2 show that different concentrations of SFGG-SJ have no toxic effect on cells; following hydrogen peroxide treatment, MIN6 cell viability was improved as the concentration of SFGG-SJ increased.
Example 14: fucogalactomannosyluronic acid polysaccharide (SFGG-SJ) derived from herba Zosterae Marinae for delaying MIN6 cell aging
As shown in FIG. 3, further examination of the cell cycle revealed that SFGG-SJ could improve H2O2The resulting cell cycle changes, the interphase of the cell cycle is divided into three phases, namely, a DNA synthesis early phase (G1 phase), a DNA synthesis phase (S phase) and a DNA synthesis late phase (G2 phase):
(1) the G1 phase (first gap) is a period from mitosis to before DNA replication, also called the pre-synthetic phase, during which RNA and ribosomes are mainly synthesized. The stage is characterized by active metabolism, rapid synthesis of RNA and protein, and significant increase of cell volume. The main meaning of this phase is to prepare the next stage S phase for DNA replication with respect to material and energy.
(2) The S phase (synthesis) is the DNA synthesis phase, during which, in addition to DNA synthesis, also histone proteins are synthesized. The enzymes required for DNA replication are all synthesized at this stage.
(3) The G2 phase (second gap) is a late stage of DNA synthesis and is a preparatory phase to mitosis. During this period, DNA synthesis is terminated, and RNA and proteins including tubulin and maturation-promoting factors are synthesized in large quantities.
As is clear from the results shown in FIG. 3, it was found that the addition of SFGG-SJ improved H2O2The cell cycle is changed, thereby achieving the effect of repairing.
Example 15: laminaria japonica-derived fucogalactomannosyluronic acid polysaccharide (SFGG-SJ) improves the expression of senescence-associated proteins in MIN6 cells
In normal human cells, inactivation of the p53 or p21 gene can prolong the replicative life of the cells, suggesting that the pathway is closely related to cellular senescence. p53 mediates the response of cells to DNA damage, p53 mediates both replicative senescence caused by telomere shortening and premature senescence caused by stress, and its downstream target molecule is p 21. p21 is an inhibitor of cyclin-dependent protein kinases and inhibits the cell cycle, causing the cell to enter irreversible growth arrest. p21 is a broad-spectrum cell cycle inhibitor, and can cause G1 phase arrest and G2 phase arrest by specifically inhibiting the protein kinase activity of cyclinD1-CDK4/CDK6, cyclinE-CDK2 and cyclinA-CDK 2.
Recent studies have found that p16INK4a has another important role in promoting the development of aging by inducing a decline in the function of stem cells in older mammals, as demonstrated at least in the bone marrow, forebrain, islet cells and keratinocytes. Treatment H with SFGG-SJ in example 12O2Model of induced aging. The senescence-associated proteins p53, p21, p16 also decreased with increasing concentration. From the above, it can be shown that SFGG-SJ can delay the aging of MIN6 cells with the increase of concentration. Also the QPCR results show that the senescence-associated metabolic phenotype is also restored.
As shown in FIG. 4, Western blot examined the expression of senescence-associated proteins p53, p21, and p16in cells, and the results showed that SFGG-SJ treatment restored senescence caused by H2O2, and that the senescence-associated proteins p53, p21, and p16 also decreased with increasing concentration.
As shown in fig. 5, qPCR detected senescence-associated secretory phenotypes such as IL-1 β, TNFa, CXCL4 and CXCL10 in cells, and it was found that the senescence-associated metabolic phenotype was also restored.
Example 16: laminaria japonica-derived fucogalactomannosyluronic acid polysaccharide (SFGG-SJ) improves function of MIN6 cell
Treatment H with SFGG-SJ in example 12O2The aging model elicited that the intracellular insulin levels increased with increasing concentrations of SFGG-SJ. Therefore SFGG-SJ can reverse H2O2Resulting in damage to insulin synthesis in islet cells.
DAPI (4', 6-diamidino-2-phenylindole): is a fluorescent dye capable of strongly binding to DNA.
Insulin is a protein hormone secreted by the beta cells of the islets of langerhans in the pancreas stimulated by endogenous or exogenous substances such as glucose, lactose, ribose, arginine, glucagon, etc.
Merge: the two fluorescence images were synthesized.
As shown in FIG. 6, intracellular insulin levels were significantly enhanced with increasing concentration of SFGG-SJ (25 → 200), while H2O2Can cause the damage of insulin synthesis, and indicates that SFGG-SJ can reverse/repair H2O2Resulting in damage to insulin synthesis in islet cells.
Claims (10)
1. The application of the sulfated fucogalactomannoglucuronan polysaccharide derived from brown algae in anti-aging is characterized in that the sulfated fucogalactomannoglucuronan polysaccharide derived from brown algae achieves the aim of anti-aging by enhancing cell activity, delaying cell aging, improving the expression of aging-related proteins of islet beta cells and improving the functions of the islet beta cells.
2. The use of claim 1, wherein the enhancing cell viability is enhancing the viability of a beta cell line.
3. The use of claim 1, wherein the retarding of cellular senescence is repairing cell cycle changes.
4. The use of claim 1, wherein said improvement in the expression of senescence-associated proteins in islet beta cells is a reduction in the expression of senescence-associated proteins p53, p21, and p16, while alleviating the senescence-associated secretory phenotypes IL-1 beta, TNFa, CXCL4, and CXCL 10.
5. The use of claim 1, wherein the improvement in islet beta cell function is repair of islet cell impairment of insulin synthesis.
6. The use of claim 1, wherein the sulfated fucgalactomannoglucuronan polysaccharide has the following characteristics: the main components of the beverage comprise monosaccharide including mannose, glucuronic acid, fucose and galactose, wherein the content of hydrolyzed sulfate groups is 2% -12%, the content of fucose is 3% -10%, and the content of uronic acid is 20% -40%.
The sulfated fucalactoglucuronan polysaccharide has the following structural characteristics:
(1) the component sugar comprises: mannose, glucuronic acid, galactose, fucose;
(2) mannose and glucuronic acid are linked by an alpha (1 → 4) glycosidic bond; glucuronic acid and mannose are linked by a β (1 → 2) glycosidic bond;
(3) the glucuronic acid and the glucuronic acid are connected by a beta (1 → 3) glycosidic bond;
(4) galactose is mainly connected by beta (1 → 6) glycosidic bond;
(5) fucose is connected with alpha (1 → 3) glycosidic bond, C2 or C4 site is sulfated; or mannose linked in a branched form by an alpha (1 → 3) glycosidic linkage;
(6) comprises the following structural units (I), (II), (III) and (IV) which are alternately connected with each other;
wherein R is1Is H or a sulfate radical, R2Is a sulfated fucose residue.
7. The use of claim 1, wherein the sulfated fucalachitomanniuronic acid polysaccharide is derived from marine brown algae including one or more of kelp, undaria pinnatifida, gulfweed, sargassum thunbergii, gulfweed, sargassum fusiforme, sargassum sal, sargassum morsella, and sargassum muticum.
8. The use of claim 1, wherein the sulfated fucgalactomannoglucuronan polysaccharide has a molecular weight of 1kD to 1000 kD.
9. The use of claim 1, wherein the method of use is the administration of an effective amount of a sulfated fucgalactomannoglucuronan as a medicament in a pharmaceutically acceptable carrier or dosage form.
10. A preparation method of sulfated fucogalactomannoglucuronan polysaccharide derived from brown algae is characterized by comprising the following steps: extracting water-soluble polysaccharide from marine brown algae by water extraction; and finally, degrading by using high-concentration acid and precipitating by using alcohol to obtain the water-soluble polysaccharide with stable strong acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111382619.XA CN113975289A (en) | 2021-11-19 | 2021-11-19 | Application of sulfated fucogalactomannoglucuronan polysaccharide from brown algae in anti-aging |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111382619.XA CN113975289A (en) | 2021-11-19 | 2021-11-19 | Application of sulfated fucogalactomannoglucuronan polysaccharide from brown algae in anti-aging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113975289A true CN113975289A (en) | 2022-01-28 |
Family
ID=79749672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111382619.XA Pending CN113975289A (en) | 2021-11-19 | 2021-11-19 | Application of sulfated fucogalactomannoglucuronan polysaccharide from brown algae in anti-aging |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113975289A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115417934A (en) * | 2022-09-02 | 2022-12-02 | 威海迪普森生物科技有限公司 | Preparation method of kelp extract with high fucooligosaccharide content |
| CN115844928A (en) * | 2022-12-16 | 2023-03-28 | 中国科学院上海药物研究所 | Seaweed sulfated polysaccharide and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103539863A (en) * | 2012-07-12 | 2014-01-29 | 中国科学院海洋研究所 | Application of low-sulfated heteroglycan prepared from brown alga and rich in glucuronic acid in preparation of medicament and health-care products for treating Parkinson's disease |
-
2021
- 2021-11-19 CN CN202111382619.XA patent/CN113975289A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103539863A (en) * | 2012-07-12 | 2014-01-29 | 中国科学院海洋研究所 | Application of low-sulfated heteroglycan prepared from brown alga and rich in glucuronic acid in preparation of medicament and health-care products for treating Parkinson's disease |
Non-Patent Citations (1)
| Title |
|---|
| JIANDONG WU等: "Structural Study of Sulfated Fuco-Oligosaccharide Branched Glucuronomannan from Kjellmaniella crassifolia by ESI-CID-MS/MS", 《JOURNAL OF CARBOHYDRATE CHEMISTRY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115417934A (en) * | 2022-09-02 | 2022-12-02 | 威海迪普森生物科技有限公司 | Preparation method of kelp extract with high fucooligosaccharide content |
| CN115417934B (en) * | 2022-09-02 | 2023-09-26 | 威海迪普森生物科技有限公司 | Preparation method of high-content fucoidin kelp extract |
| CN115844928A (en) * | 2022-12-16 | 2023-03-28 | 中国科学院上海药物研究所 | Seaweed sulfated polysaccharide and preparation method and application thereof |
| CN115844928B (en) * | 2022-12-16 | 2024-03-01 | 中国科学院上海药物研究所 | Seaweed sulfated polysaccharide and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113975289A (en) | Application of sulfated fucogalactomannoglucuronan polysaccharide from brown algae in anti-aging | |
| Jing-Wen et al. | A polysaccharide purified from Radix Adenophorae promotes cell activation and pro-inflammatory cytokine production in murine RAW264. 7 macrophages | |
| CN106084087A (en) | A kind of preparation method of Fructus Trichosanthis polysaccharide | |
| Xie et al. | Physicochemical characterization and hypoglycemic potential of a novel polysaccharide from Polygonatum sibiricum Red through PI3K/Akt mediated signaling pathway | |
| CN102432620A (en) | Resveratrol tetramer compound, its preparation method and application | |
| CN103099832B (en) | Method for biotransformation of pseudo-ginseng by using Candida | |
| CN108164614A (en) | Preparation method and the structure division characterization of a kind of pacific gelidium polysaccharide with immunoregulation effect and its application | |
| CN1965894B (en) | Prunella vulgaris polysaccharide having immune activity, preparation method and application thereof | |
| CN112321737B (en) | Oyster mushroom polysaccharide selenoside-II, preparation method thereof and application thereof in preparation of medicines for specifically killing non-small lung adenocarcinoma | |
| CN110218262B (en) | Application of low-sulfated heteroglycan rich in glucuronic acid and derived from brown algae in preparation of medicines for treating type 2 diabetes | |
| CN112274529A (en) | Application of oyster mushroom polysaccharide selenoside-III anticancer active ingredient in preparation of anti-gastric cancer medicine | |
| CN115894735B (en) | Eagle tea acidic polysaccharide, extraction and purification method and anticancer application thereof | |
| CN1190098A (en) | Preparation, medicinal composition and application of grouped gensenoside | |
| CN114933663B (en) | National medicine-ginseng low-molecular-weight water-soluble extract, homogeneous polysaccharide, oligosaccharide and total polysaccharide as well as preparation method and application thereof | |
| CN115010823B (en) | Plantain seed polysaccharide for regulating intestinal flora and preparation method and application thereof | |
| CN113480674B (en) | Black tea polysaccharide-I active ingredient, preparation method thereof and application thereof in resisting cancer | |
| CN105777854A (en) | Pharmaceutical composition of etimicin sulfate and application of pharmaceutical composition in biomedicine | |
| CN112237588B (en) | Application of oyster mushroom polysaccharide selenoside-III anticancer active ingredient in preparation of medicine for resisting prostate cancer | |
| CN102716162A (en) | Preparation technology and preparation method of panoxadiol saponins | |
| CN113248630A (en) | Fucoidin composition, preparation method and application thereof | |
| CN112979839A (en) | Preparation method of passion flower leaf acidic polysaccharide | |
| CN107213176B (en) | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof | |
| CN101486755A (en) | House lizard, preparation and medical use | |
| CN117247472B (en) | Fucoidin and preparation method and application thereof | |
| CN114437244B (en) | Lycium barbarum polysaccharide extract with lung cancer A549 cell proliferation resisting function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220128 |
|
| WD01 | Invention patent application deemed withdrawn after publication |